Abstract
RR secondary to ICI (nivolumab in all patients) were observed in the lung (n = 1) or skin (n = 3). All patients had a long-term response to ICI and are currently alive with no active disease (Median FU from ICI discontinuation: 30 months). RR could reflect a beneficial immune activation and constitute a predictive clinical biomarker of ICI long-term efficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 125-127 |
| Number of pages | 3 |
| Journal | Radiotherapy and Oncology |
| Volume | 154 |
| DOIs | |
| Publication status | Published - 1 Jan 2021 |
Keywords
- Anti CTLA4
- Anti PD-L1
- Anti-PD1
- Radioimmunotherapy